Crinetics Pharmaceuticals, Inc. (CRNX) — Analysis Summary
Crinetics Pharmaceuticals, Inc. (CRNX) has a market cap of $0.00M with year-over-year revenue growth of +640.7%. Net margin stands at -6046.2%. The stock trades at a P/E ratio of 0.0.
Key Takeaways
- Revenue changed +640.7% year-over-year
- Net margin of -6046.2%
- P/E ratio of 0.0
Compared with its sector, CRNX posted revenue growth of +640.7% and trades at a P/E of 0.0.
Crinetics Pharmaceuticals, Inc. (CRNX)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Operating margin at -1302.5% — severe operating losses
Net margin at -1189.9% — losses exceed revenue (possible one-time charges)
The latest filing shows negative free cash flow.
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.